1
|
Affandi AJ, Olesek K, Grabowska J, Nijen Twilhaar MK, Rodríguez E, Saris A, Zwart ES, Nossent EJ, Kalay H, de Kok M, Kazemier G, Stöckl J, van den Eertwegh AJM, de Gruijl TD, Garcia-Vallejo JJ, Storm G, van Kooyk Y, den Haan JMM. CD169 Defines Activated CD14 + Monocytes With Enhanced CD8 + T Cell Activation Capacity. Front Immunol 2021; 12:697840. [PMID: 34394090 PMCID: PMC8356644 DOI: 10.3389/fimmu.2021.697840] [Citation(s) in RCA: 27] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2021] [Accepted: 07/13/2021] [Indexed: 12/20/2022] Open
Abstract
Monocytes are antigen-presenting cells (APCs) that play diverse roles in promoting or regulating inflammatory responses, but their role in T cell stimulation is not well defined. In inflammatory conditions, monocytes frequently show increased expression of CD169/Siglec-1, a type-I interferon (IFN-I)-regulated protein. However, little is known about the phenotype and function of these CD169+ monocytes. Here, we have investigated the phenotype of human CD169+ monocytes in different diseases, their capacity to activate CD8+ T cells, and the potential for a targeted-vaccination approach. Using spectral flow cytometry, we detected CD169 expression by CD14+ CD16- classical and CD14+ CD16+ intermediate monocytes and unbiased analysis showed that they were distinct from dendritic cells, including the recently described CD14-expressing DC3. CD169+ monocytes expressed higher levels of co-stimulatory and HLA molecules, suggesting an increased activation state. IFNα treatment highly upregulated CD169 expression on CD14+ monocytes and boosted their capacity to cross-present antigen to CD8+ T cells. Furthermore, we observed CD169+ monocytes in virally-infected patients, including in the blood and bronchoalveolar lavage fluid of COVID-19 patients, as well as in the blood of patients with different types of cancers. Finally, we evaluated two CD169-targeting nanovaccine platforms, antibody-based and liposome-based, and we showed that CD169+ monocytes efficiently presented tumor-associated peptides gp100 and WT1 to antigen-specific CD8+ T cells. In conclusion, our data indicate that CD169+ monocytes are activated monocytes with enhanced CD8+ T cell stimulatory capacity and that they emerge as an interesting target in nanovaccine strategies, because of their presence in health and different diseases.
Collapse
Affiliation(s)
- Alsya J Affandi
- Department of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
| | - Katarzyna Olesek
- Department of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
| | - Joanna Grabowska
- Department of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
| | - Maarten K Nijen Twilhaar
- Department of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
| | - Ernesto Rodríguez
- Department of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
| | - Anno Saris
- Center for Experimental and Molecular Medicine, Amsterdam UMC, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.,Department of Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands
| | - Eline S Zwart
- Department of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.,Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
| | - Esther J Nossent
- Department of Pulmonary Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands.,Amsterdam Cardiovascular Sciences Research Institute, Amsterdam UMC, Amsterdam, Netherlands
| | - Hakan Kalay
- Department of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
| | - Michael de Kok
- Department of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
| | - Geert Kazemier
- Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
| | - Johannes Stöckl
- Institute of Immunology, Centre for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria
| | - Alfons J M van den Eertwegh
- Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
| | - Tanja D de Gruijl
- Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
| | - Juan J Garcia-Vallejo
- Department of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
| | - Gert Storm
- Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands.,Department of Biomaterials, Science and Technology, Faculty of Science and Technology, University of Twente, Enschede, Netherlands.,Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
| | - Yvette van Kooyk
- Department of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
| | - Joke M M den Haan
- Department of Molecular Cell Biology and Immunology, Cancer Center Amsterdam, Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
| |
Collapse
|
2
|
Wu G, Murugesan G, Nagala M, McCraw A, Haslam SM, Dell A, Crocker PR. Activation of regulatory T cells triggers specific changes in glycosylation associated with Siglec-1-dependent inflammatory responses. Wellcome Open Res 2021; 6:134. [PMID: 35224210 PMCID: PMC8844539 DOI: 10.12688/wellcomeopenres.16834.1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/12/2021] [Indexed: 12/28/2022] Open
Abstract
Background: Siglec-1 is a macrophage lectin-like receptor that mediates sialic acid-dependent cellular interactions. Its upregulation on macrophages in autoimmune disease was shown previously to promote inflammation through suppressing the expansion of regulatory T cells (Tregs). Here we investigate the molecular basis for Siglec-1 binding to Tregs using in vitro-induced cells as a model system. Methods: Glycosylation changes that affect Siglec‑1 binding were studied by comparing activated and resting Tregs using RNA-Seq, glycomics, proteomics and binding of selected antibodies and lectins. A proximity labelling and proteomics strategy was used to identify Siglec-1 counter-receptors expressed on activated Tregs. Results: Siglec-1 binding was strongly upregulated on activated Tregs, but lost under resting conditions. Glycomics revealed changes in N-glycans and glycolipids following Treg activation and we observed changes in expression of multiple 'glycogenes' that could lead to the observed increase in Siglec-1 binding. Proximity labelling of intact, living cells identified 49 glycoproteins expressed by activated Tregs that may function as Siglec-1 counter-receptors. These represent ~5% of the total membrane protein pool and were mainly related to T cell activation and proliferation. We demonstrate that several of these counter-receptors were upregulated following activation of Tregs and provide initial evidence that their altered glycosylation may also be important for Siglec-1 binding. Conclusions: We provide the first comprehensive analysis of glycan changes that occur in activated Tregs, leading to recognition by the macrophage lectin, Siglec-1 and suppression of Treg expansion. We furthermore provide insights into glycoprotein counter-receptors for Siglec-1 expressed by activated Tregs that are likely to be important for suppressing Treg expansion.
Collapse
Affiliation(s)
- Gang Wu
- Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee, Scotland, DD1 5EH, UK
| | - Gavuthami Murugesan
- Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee, Scotland, DD1 5EH, UK
| | - Manjula Nagala
- Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee, Scotland, DD1 5EH, UK
| | - Alex McCraw
- Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee, Scotland, DD1 5EH, UK
| | - Stuart M. Haslam
- Department of Life Sciences, Imperial College London, London, SW7 2AZ, UK
| | - Anne Dell
- Department of Life Sciences, Imperial College London, London, SW7 2AZ, UK
| | - Paul R. Crocker
- Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee, Scotland, DD1 5EH, UK
| |
Collapse
|
3
|
Abstract
A dense and diverse array of glycans on glycoproteins and glycolipids decorate all cell surfaces. In vertebrates, many of these carry sialic acid, in a variety of linkages and glycan contexts, as their outermost sugar moiety. Among their functions, glycans engage complementary glycan binding proteins (lectins) to regulate cell physiology. Among the glycan binding proteins are the Siglecs, sialic acid binding immunoglobulin-like lectins. In humans, there are 14 Siglecs, most of which are expressed on overlapping subsets of immune system cells. Each Siglec engages distinct, endogenous sialylated glycans that initiate signaling programs and regulate cellular responses. Here, we explore the emerging science of Siglec ligands, including endogenous sialoglycoproteins and glycolipids and synthetic sialomimetics. Knowledge in this field promises to reveal new molecular pathways controlling cell physiology and new opportunities for therapeutic intervention.
Collapse
|
4
|
Sun J, Lu Q, Sanmamed MF, Wang J. Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy. Clin Cancer Res 2021; 27:680-688. [PMID: 32958700 PMCID: PMC9942711 DOI: 10.1158/1078-0432.ccr-19-2925] [Citation(s) in RCA: 69] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2020] [Revised: 08/07/2020] [Accepted: 09/16/2020] [Indexed: 01/21/2023]
Abstract
Immunomodulatory agents blocking the PD-1/PD-L1 pathway have shown a new way to treat cancer. The explanation underlying the success of these agents may be the selective expression of PD-L1 with dominant immune-suppressive activities in the tumor microenvironment (TME), supporting a more favorable tumor response-to-toxicity ratio. However, despite the big success of these drugs, most patients with cancer show primary or acquired resistance, calling for the identification of new immune modulators in the TME. Using a genome-scale T-cell activity array in combination with bioinformatic analysis of human cancer databases, we identified Siglec-15 as a critical immune suppressor with broad upregulation on various cancer types and a potential target for cancer immunotherapy. Siglec-15 has unique molecular features compared with many other known checkpoint inhibitory ligands. It shows prominent expression on macrophages and cancer cells and a mutually exclusive expression with PD-L1, suggesting that it may be a critical immune evasion mechanism in PD-L1-negative patients. Interestingly, Siglec-15 has also been identified as a key regulator for osteoclast differentiation and may have potential implications in bone disorders not limited to osteoporosis. Here, we provide an overview of Siglec-15 biology, its role in cancer immune regulation, the preliminary and encouraging clinical data related to the first-in-class Siglec-15 targeting mAb, as well as many unsolved questions in this pathway. As a new player in the cancer immunotherapeutic arena, Siglec-15 may represent a novel class of immune inhibitors with tumor-associated expression and divergent mechanisms of action to PD-L1, with potential implications in anti-PD-1/PD-L1-resistant patients.
Collapse
Affiliation(s)
- Jingwei Sun
- Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut
| | - Qiao Lu
- Department of Pathology, New York University Grossman School of Medicine, New York, New York
- The Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, New York
| | - Miguel F Sanmamed
- Program of Immunology and Immunotherapy, CIMA, University of Navarra, Pamplona, Spain
| | - Jun Wang
- Department of Pathology, New York University Grossman School of Medicine, New York, New York.
- The Laura and Isaac Perlmutter Cancer Center, New York University Langone Health, New York, New York
| |
Collapse
|
5
|
Benet S, Gálvez C, Drobniewski F, Kontsevaya I, Arias L, Monguió-Tortajada M, Erkizia I, Urrea V, Ong RY, Luquin M, Dupont M, Chojnacki J, Dalmau J, Cardona P, Neyrolles O, Lugo-Villarino G, Vérollet C, Julián E, Furrer H, Günthard HF, Crocker PR, Tapia G, Borràs FE, Fellay J, McLaren PJ, Telenti A, Cardona PJ, Clotet B, Vilaplana C, Martinez-Picado J, Izquierdo-Useros N. Dissemination of Mycobacterium tuberculosis is associated to a SIGLEC1 null variant that limits antigen exchange via trafficking extracellular vesicles. J Extracell Vesicles 2021; 10:e12046. [PMID: 33489013 PMCID: PMC7807485 DOI: 10.1002/jev2.12046] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2020] [Revised: 10/28/2020] [Accepted: 12/01/2020] [Indexed: 12/14/2022] Open
Abstract
The identification of individuals with null alleles enables studying how the loss of gene function affects infection. We previously described a non-functional variant in SIGLEC1, which encodes the myeloid-cell receptor Siglec-1/CD169 implicated in HIV-1 cell-to-cell transmission. Here we report a significant association between the SIGLEC1 null variant and extrapulmonary dissemination of Mycobacterium tuberculosis (Mtb) in two clinical cohorts comprising 6,256 individuals. Local spread of bacteria within the lung is apparent in Mtb-infected Siglec-1 knockout mice which, despite having similar bacterial load, developed more extensive lesions compared to wild type mice. We find that Siglec-1 is necessary to induce antigen presentation through extracellular vesicle uptake. We postulate that lack of Siglec-1 delays the onset of protective immunity against Mtb by limiting antigen exchange via extracellular vesicles, allowing for an early local spread of mycobacteria that increases the risk for extrapulmonary dissemination.
Collapse
Affiliation(s)
- Susana Benet
- Department of Retrovirology IrsiCaixa AIDS Research Institute Badalona Spain.,Department of Retrovirology Universitat Autònoma de Barcelona Cerdanyola del Vallès Spain
| | - Cristina Gálvez
- Department of Retrovirology IrsiCaixa AIDS Research Institute Badalona Spain.,Department of Retrovirology Universitat Autònoma de Barcelona Cerdanyola del Vallès Spain
| | | | - Irina Kontsevaya
- Department of Retrovirology Imperial College London UK.,Department of Retrovirology Research Center Borstel, Borstel Germany.,Department of Retrovirology N.V. Postnikov Samara Region Clinical Tuberculosis Dispensary Samara Russia
| | - Lilibeth Arias
- Experimental Tuberculosis Unit (UTE) Germans Trias i Pujol Health Science Research Institute Can Ruti Campus Badalona Spain.,Departament de Genètica i de Microbiologia Facultat de Biociències Universitat Autònoma de Barcelona Cerdanyola del Vallès Spain.,Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES) Madrid Spain
| | - Marta Monguió-Tortajada
- REMAR-IVECAT Group Germans Trias i Pujol Health Science Research Institute Can Ruti Campus Badalona Spain.,ICREC Research Program Germans Trias i Pujol Health Science Research Institute Can Ruti Campus Badalona Spain.,Department of Cell Biology Physiology and Immunology Universitat Autònoma de Barcelona Cerdanyola del Vallès Spain
| | - Itziar Erkizia
- Department of Retrovirology IrsiCaixa AIDS Research Institute Badalona Spain
| | - Victor Urrea
- Department of Retrovirology IrsiCaixa AIDS Research Institute Badalona Spain
| | - Ruo-Yan Ong
- Division of Cell Signalling and Immunology University of Dundee Dundee UK
| | - Marina Luquin
- Departament de Genètica i de Microbiologia Facultat de Biociències Universitat Autònoma de Barcelona Cerdanyola del Vallès Spain
| | - Maeva Dupont
- Institut de Pharmacologie et Biologie Structurale IPBS CNRS UPS Université de Toulouse Toulouse France.,International associated laboratory (LIA) CNRS "IM-TB/HIV" (1167) France and Buenos Aires Toulouse Argentina
| | - Jakub Chojnacki
- Department of Retrovirology IrsiCaixa AIDS Research Institute Badalona Spain
| | - Judith Dalmau
- Department of Retrovirology IrsiCaixa AIDS Research Institute Badalona Spain
| | - Paula Cardona
- Experimental Tuberculosis Unit (UTE) Germans Trias i Pujol Health Science Research Institute Can Ruti Campus Badalona Spain.,Departament de Genètica i de Microbiologia Facultat de Biociències Universitat Autònoma de Barcelona Cerdanyola del Vallès Spain.,Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES) Madrid Spain
| | - Olivier Neyrolles
- Institut de Pharmacologie et Biologie Structurale IPBS CNRS UPS Université de Toulouse Toulouse France.,International associated laboratory (LIA) CNRS "IM-TB/HIV" (1167) France and Buenos Aires Toulouse Argentina
| | - Geanncarlo Lugo-Villarino
- Institut de Pharmacologie et Biologie Structurale IPBS CNRS UPS Université de Toulouse Toulouse France.,International associated laboratory (LIA) CNRS "IM-TB/HIV" (1167) France and Buenos Aires Toulouse Argentina
| | - Christel Vérollet
- Institut de Pharmacologie et Biologie Structurale IPBS CNRS UPS Université de Toulouse Toulouse France.,International associated laboratory (LIA) CNRS "IM-TB/HIV" (1167) France and Buenos Aires Toulouse Argentina
| | - Esther Julián
- Departament de Genètica i de Microbiologia Facultat de Biociències Universitat Autònoma de Barcelona Cerdanyola del Vallès Spain
| | - Hansjakob Furrer
- Department of Infectious Diseases Bern University Hospital University of Bern Bern Switzerland
| | - Huldrych F Günthard
- Division of Infectious Diseases and Hospital Epidemiology University Hospital Zurich Zurich Switzerland.,Institute of Medical Virology University of Zurich Zurich Switzerland
| | - Paul R Crocker
- Division of Cell Signalling and Immunology University of Dundee Dundee UK
| | - Gustavo Tapia
- Department of Retrovirology Universitat Autònoma de Barcelona Cerdanyola del Vallès Spain.,Pathology Department Hospital Universitario Germans Trias i Pujol Badalona Spain.,Germans Trias i Pujol Research Institute (IGTP) Can Ruti Campus Badalona Spain
| | - Francesc E Borràs
- REMAR-IVECAT Group Germans Trias i Pujol Health Science Research Institute Can Ruti Campus Badalona Spain.,Nephrology Department Germans Trias i Pujol University Hospital Badalona Spain
| | - Jacques Fellay
- School of Life Sciences École Polytechnique Fédérale de Lausanne Lausanne Switzerland.,Swiss Institute of Bioinformatics Lausanne Switzerland.,Precision Medicine Unit Lausanne University Hospital and University of Lausanne Lausanne Switzerland
| | - Paul J McLaren
- JC Wilt Infectious Diseases Research Centre Public Health Agency of Canada Winnipeg Manitoba Canada.,Department of Medical Microbiology and Infectious Diseases University of Manitoba Winnipeg Manitoba Canada
| | | | - Pere-Joan Cardona
- Experimental Tuberculosis Unit (UTE) Germans Trias i Pujol Health Science Research Institute Can Ruti Campus Badalona Spain.,Departament de Genètica i de Microbiologia Facultat de Biociències Universitat Autònoma de Barcelona Cerdanyola del Vallès Spain.,Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES) Madrid Spain
| | - Bonaventura Clotet
- Department of Retrovirology IrsiCaixa AIDS Research Institute Badalona Spain.,Germans Trias i Pujol Research Institute (IGTP) Can Ruti Campus Badalona Spain.,AIDS and Related Illnesses Centre for Health and Social Care Research (CESS) Faculty of Medicine University of Vic - Central University of Catalonia (UVic - UCC) Vic Spain
| | - Cristina Vilaplana
- Experimental Tuberculosis Unit (UTE) Germans Trias i Pujol Health Science Research Institute Can Ruti Campus Badalona Spain.,Departament de Genètica i de Microbiologia Facultat de Biociències Universitat Autònoma de Barcelona Cerdanyola del Vallès Spain.,Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES) Madrid Spain
| | - Javier Martinez-Picado
- Department of Retrovirology IrsiCaixa AIDS Research Institute Badalona Spain.,Germans Trias i Pujol Research Institute (IGTP) Can Ruti Campus Badalona Spain.,AIDS and Related Illnesses Centre for Health and Social Care Research (CESS) Faculty of Medicine University of Vic - Central University of Catalonia (UVic - UCC) Vic Spain.,Catalan Institution for Research and Advanced Studies (ICREA) Barcelona Spain
| | - Nuria Izquierdo-Useros
- Department of Retrovirology IrsiCaixa AIDS Research Institute Badalona Spain.,Germans Trias i Pujol Research Institute (IGTP) Can Ruti Campus Badalona Spain
| |
Collapse
|
6
|
Wielgat P, Rogowski K, Niemirowicz-Laskowska K, Car H. Sialic Acid-Siglec Axis as Molecular Checkpoints Targeting of Immune System: Smart Players in Pathology and Conventional Therapy. Int J Mol Sci 2020; 21:ijms21124361. [PMID: 32575400 PMCID: PMC7352527 DOI: 10.3390/ijms21124361] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2020] [Revised: 06/17/2020] [Accepted: 06/17/2020] [Indexed: 12/11/2022] Open
Abstract
The sialic acid-based molecular mimicry in pathogens and malignant cells is a regulatory mechanism that leads to cross-reactivity with host antigens resulting in suppression and tolerance in the immune system. The interplay between sialoglycans and immunoregulatory Siglec receptors promotes foreign antigens hiding and immunosurveillance impairment. Therefore, molecular targeting of immune checkpoints, including sialic acid-Siglec axis, is a promising new field of inflammatory disorders and cancer therapy. However, the conventional drugs used in regular management can interfere with glycome machinery and exert a divergent effect on immune controlling systems. Here, we focus on the known effects of standard therapies on the sialoglycan-Siglec checkpoint and their importance in diagnosis, prediction, and clinical outcomes.
Collapse
Affiliation(s)
- Przemyslaw Wielgat
- Department of Clinical Pharmacology, Medical University of Bialystok, Waszyngtona 15A, 15-274 Bialystok, Poland;
- Correspondence: ; Tel.: +48-85-7450-647
| | - Karol Rogowski
- Department of Experimental Pharmacology, Medical University of Bialystok, Szpitalna 37, 15-295 Bialystok, Poland; (K.R.); (K.N.-L.)
| | - Katarzyna Niemirowicz-Laskowska
- Department of Experimental Pharmacology, Medical University of Bialystok, Szpitalna 37, 15-295 Bialystok, Poland; (K.R.); (K.N.-L.)
| | - Halina Car
- Department of Clinical Pharmacology, Medical University of Bialystok, Waszyngtona 15A, 15-274 Bialystok, Poland;
- Department of Experimental Pharmacology, Medical University of Bialystok, Szpitalna 37, 15-295 Bialystok, Poland; (K.R.); (K.N.-L.)
| |
Collapse
|
7
|
Suzuki N, Abe T, Natsuka S. Quantitative LC-MS and MS/MS analysis of sialylated glycans modified by linkage-specific alkylamidation. Anal Biochem 2018; 567:117-127. [PMID: 30468716 DOI: 10.1016/j.ab.2018.11.014] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2018] [Revised: 10/17/2018] [Accepted: 11/14/2018] [Indexed: 11/25/2022]
Abstract
Sialic acids (Sia) are involved in various biological and pathological processes, and are often found attached to non-reducing ends of glycans through either α2,3- or α2,6-linkages. To quantitatively analyze glycan structures with these linkage isoforms by liquid chromatography-mass spectrometry (LC-MS), we established a linkage-specific two-step alkylamidation method for N-glycans. Using this method, carboxyl groups of α2,3- and α2,6-linked Sia are derivatized with two kinds of alkylamines with different mass values in a linkage-specific manner, allowing products to be easily distinguished. The reaction efficiencies for di-, tri-, and tetra-sialyl PA-N-glycans were >94%, with few by-products. Mixtures of 2-aminopyridine (PA)-tagged N-glycans from human α1-acid glycoprotein were subjected to the method, and products were analyzed by LC-MS and MS/MS, and simultaneously monitored with a fluorescence detector. The relative content of Siaα2-3Gal and Siaα2-6Gal was estimated from the integrated fluorescence intensity of each peak. Moreover, MS/MS data clearly indicated characteristic B-ion fragments of N-glycan branches, such as the sialyl Lex sequence, with Sia linkage-specific alkylamidation, suggesting that this method also provides useful information of branch sequences. We optimized the method with the aim of (1) enabling high-throughput analysis and (2) maximizing the analysis of glycans from various types of samples, including highly heterogeneous glycans.
Collapse
Affiliation(s)
- Noriko Suzuki
- Graduate School of Science and Technology, Niigata University, 8050 Ikarashi-nino-cho, Nishi-ku, Niigata, 950-2181, Japan.
| | - Tatsuya Abe
- Graduate School of Science and Technology, Niigata University, 8050 Ikarashi-nino-cho, Nishi-ku, Niigata, 950-2181, Japan
| | - Shunji Natsuka
- Graduate School of Science and Technology, Niigata University, 8050 Ikarashi-nino-cho, Nishi-ku, Niigata, 950-2181, Japan; Faculty of Science, Niigata University, 8050 Ikarashi-nino-cho, Nishi-ku, Niigata, 950-2181, Japan
| |
Collapse
|
8
|
Jans J, Unger WWJ, Vissers M, Ahout IML, Schreurs I, Wickenhagen A, de Groot R, de Jonge MI, Ferwerda G. Siglec-1 inhibits RSV-induced interferon gamma production by adult T cells in contrast to newborn T cells. Eur J Immunol 2018; 48:621-631. [PMID: 29266251 PMCID: PMC5947594 DOI: 10.1002/eji.201747161] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2017] [Revised: 10/29/2017] [Accepted: 12/08/2017] [Indexed: 12/12/2022]
Abstract
Interferon gamma (IFN‐γ) plays an important role in the antiviral immune response during respiratory syncytial virus (RSV) infections. Monocytes and T cells are recruited to the site of RSV infection, but it is unclear whether cell‐cell interactions between monocytes and T cells regulate IFN‐γ production. In this study, micro‐array data identified the upregulation of sialic acid‐binding immunoglobulin‐type lectin 1 (Siglec‐1) in human RSV‐infected infants. In vitro, RSV increased expression of Siglec‐1 on healthy newborn and adult monocytes. RSV‐induced Siglec‐1 on monocytes inhibited IFN‐γ production by adult CD4+ T cells. In contrast, IFN‐γ production by RSV in newborns was not affected by Siglec‐1. The ligand for Siglec‐1, CD43, is highly expressed on adult CD4+ T cells compared to newborns. Our data show that Siglec‐1 reduces IFN‐γ release by adult T cells possibly by binding to the highly expressed CD43. The Siglec‐1‐dependent inhibition of IFN‐γ in adults and the low expression of CD43 on newborn T cells provides a better understanding of the immune response against RSV in early life and adulthood.
Collapse
Affiliation(s)
- Jop Jans
- Laboratory of Pediatric Infectious Diseases, Department of Pediatrics, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands
| | - Wendy W J Unger
- Laboratory of Pediatrics, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands
| | - Marloes Vissers
- Department of Immune Mechanisms, National Institute for Public Health and the Environment, Bilthoven, The Netherlands
| | - Inge M L Ahout
- Laboratory of Pediatric Infectious Diseases, Department of Pediatrics, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands
| | - Inge Schreurs
- Laboratory of Pediatric Infectious Diseases, Department of Pediatrics, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands
| | - Arthur Wickenhagen
- Laboratory of Pediatric Infectious Diseases, Department of Pediatrics, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands
| | - Ronald de Groot
- Laboratory of Pediatric Infectious Diseases, Department of Pediatrics, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands
| | - Marien I de Jonge
- Laboratory of Pediatric Infectious Diseases, Department of Pediatrics, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands
| | - Gerben Ferwerda
- Laboratory of Pediatric Infectious Diseases, Department of Pediatrics, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands
| |
Collapse
|
9
|
Abstract
Lectin-glycan interactions play important roles in many biological systems, but the nature of glycoprotein counter-receptors expressed on cell membranes is often poorly understood. To help overcome this problem, we developed a method based on proximity labeling technology. Using a peroxidase-coupled lectin, addition of H2O2 and tyramide-biotin substrates leads to generation of short-range biotin radicals that biotinylate proteins in the immediate vicinity of the bound lectin, which can subsequently be identified. As a proof-of-principle, sialoadhesin-horseradish peroxidase-human IgG1 Fc recombinant protein constructs were precomplexed with anti-Fc antibodies, bound to human erythrocytes and reacted with H2O2 and tyramide-SS-biotin. The erythrocyte membrane protein with strongest biotinylation was identified as glycophorin A, in agreement with early studies using lectin overlay and reglycosylation approaches. As a further test of the method, the plant lectin MAL II was conjugated with horseradish peroxidase and used in proximity labeling of human erythrocytes. Glycophorin A was again selectively labeled, which is consistent with previous reports that MAL II has high affinity for glycophorin. This method could be applied to other lectins to identify their membrane counter-receptors.
Collapse
Affiliation(s)
- Gang Wu
- Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, The Wellcome Trust Building, Dow Street, Dundee DD1 5EH, UK
| | - Manjula Nagala
- Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, The Wellcome Trust Building, Dow Street, Dundee DD1 5EH, UK
| | - Paul R Crocker
- Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, The Wellcome Trust Building, Dow Street, Dundee DD1 5EH, UK
| |
Collapse
|
10
|
Abstract
Lectins recognize a diverse array of carbohydrate structures and perform numerous essential biological functions. Here we focus on only two families of lectins, the Siglecs and C-type lectins. Triggering of intracellular signaling cascades following ligand recognition by these receptors can have profound effects on the induction and modulation of immunity. In this chapter, we provide a brief overview of each family and then focus on selected examples that highlight how these lectins can influence myeloid cell functioning in health and disease. Receptors that are discussed include Sn (Siglec-1), CD33 (Siglec-3), and Siglec-5, -7, -8, -9, -10, -11, -14, -15, -E, -F, and -G as well as Dectin-1, MICL, Dectin-2, Mincle/MCL, and the macrophage mannose receptor.
Collapse
|
11
|
Abstract
Many Siglecs function as inhibitory receptors on innate and adaptive immune cells and may contribute to the attenuation of immune responses to tumors. Siglec 9 on neutrophils and Siglec 7 on NK cells are prominent examples of inhibitory Siglecs that can potentially dampen anti-tumor immunity. CD169 is a Siglec that may function as an adhesion molecule and a facilitator of the recognition and internalization of sialic acid decorated apoptotic bodies and exosomes derived from tumors. It can potentially contribute to both the attenuation as well as the facilitation of anti-tumor immunity. Siglecs have been best studied in the tumor context in animal models of cancer. Modulators of Siglec function are likely to be developed and investigated clinically in a cancer context over the next few years.
Collapse
Affiliation(s)
- Isabella Fraschilla
- Ragon Institute of MGH, MIT and Harvard, Harvard Medical School, Cambridge, MA, USA
| | - Shiv Pillai
- Ragon Institute of MGH, MIT and Harvard, Harvard Medical School, Cambridge, MA, USA
| |
Collapse
|
12
|
Eakin AJ, Bustard MJ, McGeough CM, Ahmed T, Bjourson AJ, Gibson DS. Siglec-1 and -2 as potential biomarkers in autoimmune disease. Proteomics Clin Appl 2016; 10:635-44. [DOI: 10.1002/prca.201500069] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2015] [Revised: 11/25/2015] [Accepted: 01/05/2016] [Indexed: 11/06/2022]
Affiliation(s)
- Amanda J. Eakin
- Northern Ireland Centre for Stratified Medicine; Altnagelvin Hospital Campus; Ulster University; Londonderry Northern Ireland UK
| | - Michael J. Bustard
- Northern Ireland Centre for Stratified Medicine; Altnagelvin Hospital Campus; Ulster University; Londonderry Northern Ireland UK
| | - Cathy M. McGeough
- Northern Ireland Centre for Stratified Medicine; Altnagelvin Hospital Campus; Ulster University; Londonderry Northern Ireland UK
| | - Tahanver Ahmed
- Northern Ireland Centre for Stratified Medicine; Altnagelvin Hospital Campus; Ulster University; Londonderry Northern Ireland UK
| | - Anthony J. Bjourson
- Northern Ireland Centre for Stratified Medicine; Altnagelvin Hospital Campus; Ulster University; Londonderry Northern Ireland UK
| | - David S. Gibson
- Northern Ireland Centre for Stratified Medicine; Altnagelvin Hospital Campus; Ulster University; Londonderry Northern Ireland UK
| |
Collapse
|
13
|
Liou LB, Huang CC. Sialyltransferase and Neuraminidase Levels/Ratios and Sialic Acid Levels in Peripheral Blood B Cells Correlate with Measures of Disease Activity in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Pilot Study. PLoS One 2016; 11:e0151669. [PMID: 26981635 PMCID: PMC4794174 DOI: 10.1371/journal.pone.0151669] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2015] [Accepted: 03/02/2016] [Indexed: 11/18/2022] Open
Abstract
Objective We attempted to determine whether the level of enzymes sialyltransferase (ST) and neuraminidase (Neu) and sialic acid (SIA) in patients with systemic lupus erythematosus (SLE) correlates with the SLE Disease Activity Index (SLEDAI) and in patients with rheumatoid arthritis (RA) correlates with the Disease Activity Score28 (DAS28). Methods We examined cell-surface levels of ST6Gal-1, Neu1, ST3Gal-1, Neu3, α-2,6-SIA, and α-2,3-SIA by using fluorescent anti-enzyme antibodies, fluorescent-conjugated Sambucus nigra lectin, and fluorescent-conjugated Maackia amurensis lectin on blood cells in SLE and RA patients and assessed correlations of these levels with SLEDAI and with DAS28. Areas under the curve (AUC) were calculated for different variables against SLEDAI. Results The B-cell ST3Gal-1/Neu3 ratio positively correlated with SLEDAI scores (ρ = 0.409 and P = 0.002, statistically significant after Bonferroni’ correction for multiple analyses.). It was supported by the inverse correlation of B-cell Neu3 levels with SLEDAI scores (ρ = −0.264, P = 0.048). The B-cell ST3Gal-1/Neu3 ratio against SLEDAI yielded an AUC of 0.689, which was comparable to that of anti-dsDNA levels at 0.635. In contrast, both ST3Gal-1 and Neu3 levels of RA B cells (r = 0.376, P = 0.013; r = 0.425, P = 0.005, respectively) correlated positively with high disease-activity DAS28 scores. Conclusion B-cell ST3Gal-1/Neu3 ratios in SLE and B-cell ST3Gal-1 and Neu3 levels in RA with high disease-activity DAS28 scores correlated with disease activity measures and may be useful in monitoring disease activities.
Collapse
Affiliation(s)
- Lieh-bang Liou
- Division of Rheumatology, Allergy, and Immunology, Chang Gung Memorial Hospital at Lin-kou, Kwei-san District, Tao-yuan City, Taiwan
- Chang Gung University College of Medicine, Kwei-san District, Tao-yuan City, Taiwan
- * E-mail: ;
| | - Che-ching Huang
- Division of Rheumatology, Allergy, and Immunology, Chang Gung Memorial Hospital at Lin-kou, Kwei-san District, Tao-yuan City, Taiwan
| |
Collapse
|
14
|
Groh J, Ribechini E, Stadler D, Schilling T, Lutz MB, Martini R. Sialoadhesin promotes neuroinflammation-related disease progression in two mouse models of CLN disease. Glia 2016; 64:792-809. [PMID: 26775238 DOI: 10.1002/glia.22962] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2015] [Revised: 12/15/2015] [Accepted: 12/17/2015] [Indexed: 01/13/2023]
Abstract
CLN diseases are mostly fatal lysosomal storage diseases that lead to neurodegeneration in the CNS. We have previously shown that CD8+ T-lymphocytes contribute to axonal perturbation and neuron loss in the CNS of Ppt1(-/-) mice, a model of CLN1 disease. We now investigated the role of the inflammation-related cell adhesion molecule sialoadhesin (Sn) in Ppt1(-/-) and Cln3(-/-) mice, a model of the most frequent form, CLN3 disease. Microglia/macrophages in the CNS of both models showed an upregulation of Sn and markers for proinflammatory M1 polarization and antigen presentation. Sn+ microglia/macrophages associated with SMI32+ axonal spheroids and CD8+ T-lymphocytes. To analyze their pathogenic impact, we crossbred both models with Sn-deficient mice and scored axonal degeneration and neuronal integrity using immunohistochemistry, electron microscopy and optical coherence tomography. Degenerative alterations in the retinotectal pathway of Ppt1(-/-)Sn(-/-) and Cln3(-/-)Sn(-/-) mice were significantly reduced. Ppt1(-/-)Sn(-/-) mice also showed a substantially improved clinical phenotype and extended lifespan, attenuated numbers of M1-polarized microglia/macrophages and reduced expression levels of proinflammatory cytokines. This was accompanied by an increased frequency of CD8+CD122+ T-lymphocytes in the CNS of Ppt1(-/-)Sn(-/-) mice, the regulatory phenotype of which was demonstrated by impaired survival of CD8+CD122- effector T-lymphocytes in co-culture experiments. We show for the first time that increased Sn expression on microglia/macrophages contributes to neural perturbation in two distinct models of CLN disease. Our data also indicate that a rarely described CD8+CD122+ T-cell population can regulate the corresponding diseases. These studies provide insights into CLN pathogenesis and may guide in designing immuno-regulatory treatment strategies.
Collapse
Affiliation(s)
- Janos Groh
- Department of Neurology, Developmental Neurobiology, University Hospital Wuerzburg, Wuerzburg, Germany
| | - Eliana Ribechini
- Institute of Virology and Immunobiology, University of Wuerzburg, Wuerzburg, Germany
| | - David Stadler
- Department of Neurology, Developmental Neurobiology, University Hospital Wuerzburg, Wuerzburg, Germany
| | - Tim Schilling
- Department of Neurology, Developmental Neurobiology, University Hospital Wuerzburg, Wuerzburg, Germany
| | - Manfred B Lutz
- Institute of Virology and Immunobiology, University of Wuerzburg, Wuerzburg, Germany
| | - Rudolf Martini
- Department of Neurology, Developmental Neurobiology, University Hospital Wuerzburg, Wuerzburg, Germany
| |
Collapse
|
15
|
Abstract
All mammalian cells display a diverse array of glycan structures that differ from those that are found on microbial pathogens. Siglecs are a family of sialic acid-binding immunoglobulin-like receptors that participate in the discrimination between self and non-self, and that regulate the function of cells in the innate and adaptive immune systems through the recognition of their glycan ligands. In this Review, we describe the recent advances in our understanding of the roles of Siglecs in the regulation of immune cell function in infectious diseases, inflammation, neurodegeneration, autoimmune diseases and cancer.
Collapse
Affiliation(s)
- Matthew S Macauley
- Departments of Cell and Molecular Biology, Immunology and Microbial Science, and Physiological Chemistry, The Scripps Research Institute, La Jolla, California 92037, USA
| | - Paul R Crocker
- Division of Cell Signalling and Immunology, Wellcome Trust Building, College of Life Sciences, University of Dundee, Dundee DD1 5EH, UK
| | - James C Paulson
- Departments of Cell and Molecular Biology, Immunology and Microbial Science, and Physiological Chemistry, The Scripps Research Institute, La Jolla, California 92037, USA
| |
Collapse
|
16
|
Naito-Matsui Y, Takada S, Kano Y, Iyoda T, Sugai M, Shimizu A, Inaba K, Nitschke L, Tsubata T, Oka S, Kozutsumi Y, Takematsu H. Functional evaluation of activation-dependent alterations in the sialoglycan composition of T cells. J Biol Chem 2013; 289:1564-79. [PMID: 24297165 DOI: 10.1074/jbc.m113.523753] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
Sialic acids (Sias) are often conjugated to the termini of cellular glycans and are key mediators of cellular recognition. Sias are nine-carbon acidic sugars, and, in vertebrates, the major species are N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc), differing in structure at the C5 position. Previously, we described a positive feedback loop involving regulation of Neu5Gc expression in mouse B cells. In this context, Neu5Gc negatively regulated B-cell proliferation, and Neu5Gc expression was suppressed upon activation. Similarly, resting mouse T cells expressed principally Neu5Gc, and Neu5Ac was induced upon activation. In the present work, we used various probes to examine sialoglycan expression by activated T cells in terms of the Sia species expressed and the linkages of Sias to glycans. Upon T-cell activation, sialoglycan expression shifted from Neu5Gc to Neu5Ac, and the linkage shifted from α2,6 to α2,3. These changes altered the expression levels of sialic acid-binding immunoglobulin-like lectin (siglec) ligands. Expression of sialoadhesin and Siglec-F ligands increased, and that of CD22 ligands decreased. Neu5Gc exerted a negative effect on T-cell activation, both in terms of the proliferative response and in the context of activation marker expression. Suppression of Neu5Gc expression in mouse T and B cells prevented the development of nonspecific CD22-mediated T cell-B cell interactions. Our results suggest that an activation-dependent shift from Neu5Gc to Neu5Ac and replacement of α2,6 by α2,3 linkages may regulate immune cell interactions at several levels.
Collapse
|
17
|
Kidder D, Richards HE, Lyons PA, Crocker PR. Sialoadhesin deficiency does not influence the severity of lupus nephritis in New Zealand black x New Zealand white F1 mice. Arthritis Res Ther 2013; 15:R175. [PMID: 24286366 PMCID: PMC3978688 DOI: 10.1186/ar4364] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2013] [Accepted: 10/11/2013] [Indexed: 02/06/2023] Open
Abstract
INTRODUCTION Systemic lupus erythematosus (SLE) is a chronic inflammatory condition with multisystem involvement. One of the key features of the disease is the upregulation of type I interferons, resulting in the so-called "interferon signature". Recent flow cytometric and transcriptomic studies identified Sialoadhesin (Sn, CD169) as an important interferon-induced blood monocyte biomarker in diseased patients. To investigate a potential causative role of Sn in SLE, we generated NZBWF1 (New Zealand Black x New Zealand White F1) mice lacking Sn and compared onset and progression of disease with NZBWF1 expressing normal levels of Sn. METHODS Sn expression in renal tissues of pre-diseased and diseased NZBWF1 mice was evaluated by Quantitative real time PCR (QPCR) and immunohistochemistry. Sn-/- NZBWF1 mice were generated by speed congenics. Disease severity of Sn+/+ and Sn-/- NZBWF1 mice was assessed by serum immunoassays, flow cytometry, light microscopy and immunohistochemistry. RESULTS Renal tissues from proteinuric NZBWF1 mice exhibited a significant upregulation of Sn mRNA and protein expression following disease onset. Further immunohistochemical analysis showed that Sn+ macrophages assumed a distinct periglomerular distribution and, unlike CD68+ macrophages, were not present within the glomeruli. Analysis of disease severity in Sn-/- and Sn+/+ NZBWF1 mice revealed no significant differences in the disease progression between the two groups although Sn-deficient mice showed a more rapid onset of proteinuria. CONCLUSIONS These data confirm a positive correlation of Sn with disease activity. However, Sn deficiency does not have a significant effect on the severity and progression of lupus nephritis in the NZBWF1 mouse model.
Collapse
|